Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Percheron Therapeutics ( (AU:PER) ).
Percheron Therapeutics Limited has announced its Annual General Meeting scheduled for October 22, 2025, which will be held both in person and virtually. The meeting will cover the consideration of the 2025 Annual Financial Report and a non-binding resolution to adopt the 2025 Remuneration Report. This meeting is significant for stakeholders as it provides insights into the company’s financial health and governance practices, although the resolutions are advisory and non-binding.
The most recent analyst rating on (AU:PER) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Percheron Therapeutics Limited operates in the pharmaceutical industry, focusing on therapeutic solutions. The company is engaged in the development and commercialization of innovative treatments, aiming to address unmet medical needs within its market focus.
Average Trading Volume: 4,290,184
Technical Sentiment Signal: Sell
Current Market Cap: A$10.87M
For detailed information about PER stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “…Supporting the Responsible Growth of our Industry…” Boeing Stock (NYSE:BA) Notches Up With Carbon Purchase
- “Secure Foundations for the Era of Frontier AI”: Microsoft Stock (NASDAQ:MSFT) Gains With New AI Plans
- Elon Musk Made $158 Billion in 2025, But Received None of It. Tesla Stock (NASDAQ:TSLA) Surges

